Form 4: Director Mark McKenna Receives Apogee Therapeutics Options

Director Mark McKenna was granted 7,657 stock options in Apogee Therapeutics, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Mark McKenna received a grant of 7,657 stock options on June 9, 2026.
• The options have an exercise price of $85.00 per share.
• The options are scheduled to vest in full on the one-year anniversary of the grant date, June 9, 2027.
• The expiration date for these options is June 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of Apogee Therapeutics common stock.

Future Outlook

The options vest on June 9, 2027, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure alignment between board members and shareholders, particularly for companies in the development stage.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard corporate governance practices for NASDAQ-listed biotechnology firms.
• The one-year cliff vesting schedule is a common retention mechanism used by peer companies in the life sciences industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 9, 2027.

Key Dates

Keywords

Apogee Therapeutics, APGE, Director Compensation, Stock Options, Insider Transaction, Form 4